Upload fondas-vakalis
View 524
Download 1
Embed Size (px) 344 x 292 429 x 357 514 x 422 599 x 487
Citation preview
PSS 8 IHC in NSCLC webcast 3
Brain Metastases in NSCLC Boone Goodgame, MD
Treatment of ALK Positive Advanced NSCLC · Treatment of ALK Positive Advanced NSCLC ... • First identified in NSCLC cells in 2007 ... Chemistry of ALK Tyrosine Kinase Inhibitors
Early Stage Nsclc The Role Of Chemotherapy
NSCLC - InOncology · 2020-06-15 · NSCLC, the most common type of lung cancer, is genomically diverse ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; NSCLC,
Biomarker testing in non- small cell lung cancer (NSCLC) · NSCLC is both histologically and genetically diverse. 3. Prevalence of genetic alterations in NSCLC. 4. 40%. 25%. 10%
Current standard of care of NSCLC · First TKI versus chemotherapy in EGFR mutated NSCLC. Mok, NEJM 2009. Rosell, Lancet Oncol 2012. First-line TKI therapy in EGFR-mutated NSCLC:
Squamous Cell NSCLC Are we making progress?
NSCLC: Targeted Therapies and Beyond · approved for the treatment of NSCLC. There are also drugs that target specific NSCLC–associated mutations. For example, 10-35 percent of
Improving Outcomes in Advanced NSCLC with Immune ...•5-year survival rate is 19% (NSCLC + SCLC) •From 2009–2015, the relative survival rate for NSCLC was 25% •Recent overall
Immunotherapy in NSCLC
CCO Metastatic NSCLC Slides
Risultati e prospettive nel NSCLC - Sacro Cuoreweb2.sacrocuore.it/oncologia/Oncologia_18sett15/Sesta_Sessione/05... · Risultati e prospettive nel NSCLC ... Delayed effect of nivolumab
Nsclc slide deck
Nsclc 2nd line
NSCLC. NSCLC 85% of lung cancers Non-squamous Adenocarcinoma (subtypes based on gene expression) 1.Broncioid (associated with increased survival
Targeting oncogenic drivers in NSCLC - OncologyPROoncologypro.esmo.org/content/download/98588/1730732/file/ESMO... · Targeting oncogenic drivers in NSCLC ... ETOP sponsored,
Maintenance therapy for NSCLC
Systemic therapy for non-oncogene addicted NSCLC
Mlm nsclc prevencion_oportuno_2016_b
First Response: NSCLC Highlights From Chicago
Treating second-line and beyond in non-mutated, non ... · 3ESMO 2018 Congress, Munich, Germany, 19 Nonsquamous NSCLC • NSCLC accounts for 85%-90% of lung cancers1 – ADC accounts
ADJUVANT THERAPY IN OLDER ADULTS: NSCLC
Locally Advanced Nsclc
Treatment strategies for oncogenic addicted NSCLC patients
From Inquiry to Investigation to Insight: Clinical Clarity in … · 2019. 12. 6. · EGFR in NSCLC •10% of NSCLC cases in North America •30%–50% of NSCLC cases in East Asia
Chemo rt in nsclc 2011- jk
Update Nsclc
Management of NSCLC
ESMO E-Learning: Management of Advanced NSCLC: …oncologypro.esmo.org/content/download/38068/749531/file/managemen… · cancer (NSCLC) cisplatin or carboplatin combination therapies
